香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該 等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站 (http://www.sse.com.cn)刊登的《上海醫藥集團股份有限公司關於 2019 年 A 股股 票期權激勵計劃預留股票期權第三個行權期限制行權期間的提示性公告》僅供參 閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 12 月 19 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601607 证券简称：上海医药 编号：临 2025-1 ...

一、预留股票期权第三个行权期自2025年2月8日起至2026年2月7日止。 二、本次限制行权期为2025年12月22日至2026年1月5日，在此期间全部激励 对象将限制行权。 证券代码：601607 证券简称：上海医药 编号：临 2025-117 上海医药集团股份有限公司 关于 2019 年 A 股股票期权激励计划 预留股票期权第三个行权期限制行权期间的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上市公司股权激励管理办法》、《上海证券交易所上市公司自律监管 指南第2号—业务办理》、《上海医药集团股份有限公司2019年股票期权激励计 划》及中国证券登记结算有限责任公司上海分公司（以下简称"中证登上海分公 司"）关于股票期权自主行权的相关规定，并结合上海医药集团股份有限公司（以 下简称"公司"）2025半年度权益分派计划，现对公司2019年股票期权激励计划 预留股票期权第三个行权期限制行权期间（以下简称"本次限制行权期"）公告 如下： 三、公司将按照有关规定及时向中证登上海分公司申请办理限制行权相关事 ...

Core Viewpoint - The A-share pharmaceutical retail sector has experienced a significant rise, with the overall sector increasing by 5.73%, driven by renewed market recognition of the long-term growth logic in the pharmaceutical commercial industry [1][4]. Group 1: Market Performance - The pharmaceutical commercial sector saw a strong performance, with several stocks hitting the daily limit, including Huaren Health and Yiyuan Group, indicating a broad-based rally within the sector [1]. - The demand for protective products has directly translated into increased sales for retail pharmacies, effectively supporting the industry's overall prosperity [1]. Group 2: Industry Dynamics - The pharmaceutical retail industry is transitioning from rapid expansion to a phase of consolidation, with a notable decrease in the number of physical pharmacies, which has been declining for two consecutive quarters since Q4 2024 [2][3]. - The top 10 chain pharmacies are exhibiting significantly lower closure rates compared to smaller chains, leading to a concentration of market share among leading companies [3]. Group 3: Future Outlook - The growth path for industry leaders is becoming clearer, driven by both internal growth through improved product structure and external growth via mergers and acquisitions [3]. - Analysts believe that the recent surge in the pharmaceutical commercial sector reflects a re-evaluation of the industry's value, with a shift from being seen merely as "transporters" to key nodes in the health service ecosystem [4].

Core Viewpoint - Shanghai Pharmaceuticals has received approval for its innovative drug, Suojirolin, aimed at treating primary hypertension, marking a significant achievement in its commitment to independent innovation in the pharmaceutical industry [1][2]. Group 1: Product Approval and Clinical Significance - The National Medical Products Administration (NMPA) has officially approved Suojirolin (brand name: Xintuoan), a first-class innovative drug for the treatment of primary hypertension [1]. - Suojirolin is a new generation of oral non-peptide small molecule renin inhibitors, designed to meet unmet clinical needs, providing a new treatment option for over 300 million patients with primary hypertension in China [1]. - Clinical trials have shown that Suojirolin demonstrates good efficacy and safety, with its Phase II trial results published in the authoritative journal "Hypertension Research," indicating growing global academic interest in Chinese innovative drugs [1]. Group 2: Research and Development Strategy - Shanghai Pharmaceuticals has positioned research and development (R&D) innovation at its strategic core, with a planned R&D investment of 2.818 billion yuan for 2024, leading the industry in investment intensity [2]. - As of the end of Q3 2025, the company has submitted 57 new drug applications for clinical trials, including 45 innovative drug pipelines, establishing a comprehensive and tiered R&D team [2]. - The company has several innovative drugs in advanced clinical stages, including a CD20 injection for neuromyelitis optica and a traditional Chinese medicine for cervical spondylosis, indicating a robust pipeline [2]. Group 3: Collaborative Innovation and Market Strategy - Shanghai Pharmaceuticals has established the Shanghai Frontier Biomedical Innovation Center to foster an open innovation ecosystem by collaborating with top universities and research institutions [3]. - The company has created a comprehensive distribution network covering over 80,000 medical institutions across 25 provinces and municipalities in China, ensuring effective market access for Suojirolin [3]. - The integration of online and offline pharmaceutical services enhances the company's ability to reach patients quickly and efficiently [3].

Core Viewpoint - Shanghai Pharmaceuticals has received approval for its Hydroxychloroquine Sulfate Tablets from the Philippines Food and Drug Administration, allowing the product to be marketed [1] Group 1 - The product is manufactured by Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceuticals [1] - The approval signifies a potential expansion of the company's market presence in the pharmaceutical sector [1]

Group 1 - Shareholder Zhang Yu of Kehua Holdings plans to reduce his stake by up to 3%, amounting to no more than 5.83 million shares within three months [1] - Shanghai Ailu has signed a strategic cooperation agreement with Southern Road Machinery to provide packaging products for the dry-mixed mortar industry [2] - Xingyuan Zhuomei appointed Gong Chunming as the new deputy general manager [3] Group 2 - Tongyi Zhong's shareholder has set a preliminary transfer price of 15.47 yuan per share for a total of 4.27 million shares [4] - Anada's shareholder did not implement the planned share reduction of up to 2% by the deadline [5] - Rongchang Bio plans to repurchase shares worth between 20 million to 40 million yuan at a price not exceeding 95 yuan per share [6] Group 3 - Hainan Airport reported an 8.16% year-on-year increase in passenger throughput for November, totaling 2.09 million passengers [7] - Lanjian Intelligent plans to apply for a bank credit line of up to 1.2 billion yuan for various financial operations [8] - Xinlei Co. received a total of 561.43 million yuan in land acquisition and compensation payments [9] Group 4 - Foster reported a surplus of 321 million yuan from four fundraising projects, which will be used to supplement working capital [10] - China Southern Airlines experienced a 10.42% year-on-year increase in passenger turnover for November [12] - China National Airlines reported a 10.1% year-on-year increase in passenger turnover for November [17] Group 5 - Sanyou Chemical plans to register and issue mid-term notes not exceeding 1.3 billion yuan [18] - Quanyuan Spring used 60 million yuan of idle funds to purchase structured deposits [19] - Su Keng Agricultural Development appointed Zou Yi as the new deputy general manager [20] Group 6 - Jingneng Real Estate received approval to register mid-term notes totaling up to 2 billion yuan [21] - Dechang Co. received approval from the CSRC for a targeted issuance of shares [23] - Jiufeng Bio obtained a medical device registration certificate for its fructosamine testing kit [24] Group 7 - Jinzi Ham's president Guo Bo resigned for personal reasons, while Zheng Hu was appointed as the new president [25] - China Eastern Airlines reported a 10.35% year-on-year increase in passenger turnover for November [26] - Fengfan Co.'s controlling shareholder is in the process of acquiring 17.32% of the company's shares [27] Group 8 - Zhenghai Bio signed a technical development contract with the Chinese Academy of Agricultural Sciences for a collagen product project worth 12 million yuan [28] - Xinhua Insurance reported a 16% year-on-year increase in cumulative original insurance premium income for the first 11 months [29] - Jingjia Microelectronics' subsidiary completed key stages of its AI SoC chip project [30] Group 9 - Shanghai Pharmaceuticals' hydrochloride sotalol tablets passed the consistency evaluation for generic drugs [31] - Heshun Technology's subsidiary's carbon fiber project has entered a stable operational phase [32] - Spring Airlines reported an 18.02% year-on-year increase in passenger turnover for November [33] Group 10 - Huaxin New Materials proposed a mid-term dividend plan of 1 yuan per 10 shares [34] - Keda Li plans to increase capital by 300 million yuan for its wholly-owned subsidiary [35] - Jinguang Electric won a bid for a high-voltage direct current transmission project worth 84.86 million yuan [36] Group 11 - XGIMI Technology's subsidiary received a development notification for a vehicle-mounted projection project from a well-known domestic automotive manufacturer [37]

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Changzhou Pharmaceutical Factory, received approval from the National Medical Products Administration for the hydrochloride sotalol tablets, which passed the consistency evaluation of generic drug quality and efficacy [1] Group 1: Company Information - The hydrochloride sotalol tablets are primarily used for the conversion and prevention of supraventricular tachycardia, atrial flutter, atrial fibrillation, and various ventricular arrhythmias [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607) has received a drug registration certificate from the Philippines Food and Drug Administration for its Hydroxychloroquine Sulfate Tablets, allowing the company to sell the product in the Philippines, which is expected to positively impact its overseas market expansion [1] Group 1: Product Approval - The Hydroxychloroquine Sulfate Tablets are primarily used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, and skin diseases exacerbated by sunlight [1] - The product was developed by Concordia Pharmaceuticals Inc and was first launched in the United States in 1955 [1] - Shanghai Pharmaceuticals' Hydroxychloroquine Sulfate Tablets were approved for domestic sale in China in December 1999 and passed the consistency evaluation for generic drugs in December 2021 [1] Group 2: Financial Aspects - The company has not incurred additional R&D expenses for the product's launch in the Philippines, with only registration-related costs amounting to approximately RMB 50,000 [1] - According to IQVIA data, the total sales revenue for Hydroxychloroquine Sulfate Tablets (200 mg) in the Philippines is projected to be USD 4.13 million in 2024 [1] Group 3: Market Impact - The approval signifies the company's qualification to sell the product in the Philippine market, which is expected to have a positive impact on the company's overseas market expansion and accumulate valuable experience [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has received a drug registration certificate from the Philippines Food and Drug Administration for Hydroxychloroquine Sulfate Tablets, which are now approved for market launch [1] Group 1 - The approved drug, Hydroxychloroquine Sulfate Tablets, is primarily used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin diseases triggered or exacerbated by sunlight [1]

Group 1 - Shanghai Pharmaceuticals (601607) subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has received a drug registration certificate from the Philippines Food and Drug Administration for Hydroxychloroquine Sulfate Tablets, allowing the product to be marketed [1] - Hydroxychloroquine Sulfate Tablets are primarily used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin diseases triggered or exacerbated by sunlight [1]